123 related articles for article (PubMed ID: 38142230)
21. Diffusion-weighted MRI at 3.0 T for detection of occult disease in the contralateral breast in women with newly diagnosed breast cancer.
Ha SM; Chang JM; Lee SH; Kim ES; Kim SY; Cho N; Moon WK
Breast Cancer Res Treat; 2020 Jul; 182(2):283-297. PubMed ID: 32447596
[TBL] [Abstract][Full Text] [Related]
22. Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial.
Veenhuizen SGA; de Lange SV; Bakker MF; Pijnappel RM; Mann RM; Monninkhof EM; Emaus MJ; de Koekkoek-Doll PK; Bisschops RHC; Lobbes MBI; de Jong MDF; Duvivier KM; Veltman J; Karssemeijer N; de Koning HJ; van Diest PJ; Mali WPTM; van den Bosch MAAJ; van Gils CH; Veldhuis WB;
Radiology; 2021 May; 299(2):278-286. PubMed ID: 33724062
[TBL] [Abstract][Full Text] [Related]
23. Predictive values of BI-RADS(®) magnetic resonance imaging (MRI) in the detection of breast ductal carcinoma in situ (DCIS).
Badan GM; Piato S; Roveda D; de Faria Castro Fleury E
Eur J Radiol; 2016 Oct; 85(10):1701-1707. PubMed ID: 27666605
[TBL] [Abstract][Full Text] [Related]
24. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
[TBL] [Abstract][Full Text] [Related]
25. MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion.
Nadler M; Al-Attar H; Warner E; Martel AL; Balasingham S; Zhang L; Lipton JH; Curpen B
Breast; 2017 Aug; 34():77-82. PubMed ID: 28527397
[TBL] [Abstract][Full Text] [Related]
26. Performance of Screening Breast MRI After Negative Full-Field Digital Mammography Versus After Negative Digital Breast Tomosynthesis in Women at Higher Than Average Risk for Breast Cancer.
Roark AA; Dang PA; Niell BL; Halpern EF; Lehman CD
AJR Am J Roentgenol; 2019 Feb; 212(2):271-279. PubMed ID: 30540208
[TBL] [Abstract][Full Text] [Related]
27. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
Fonseca MM; Alhassan T; Nisha Y; Koszycki D; Schwarz BA; Segal R; Arnaout A; Ramsay T; Lau J; Seely JM
BMC Cancer; 2022 Jul; 22(1):774. PubMed ID: 35840916
[TBL] [Abstract][Full Text] [Related]
29. Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy.
Cho N; Han W; Han BK; Bae MS; Ko ES; Nam SJ; Chae EY; Lee JW; Kim SH; Kang BJ; Song BJ; Kim EK; Moon HJ; Kim SI; Kim SM; Kang E; Choi Y; Kim HH; Moon WK
JAMA Oncol; 2017 Nov; 3(11):1495-1502. PubMed ID: 28655029
[TBL] [Abstract][Full Text] [Related]
30. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
[TBL] [Abstract][Full Text] [Related]
31. Frequency and Cancer Yield of BI-RADS Category 3 Lesions Detected at High-Risk Screening Breast MRI.
Edmonds CE; Lamb LR; Mercaldo SF; Sippo DA; Burk KS; Lehman CD
AJR Am J Roentgenol; 2020 Feb; 214(2):240-248. PubMed ID: 31799867
[No Abstract] [Full Text] [Related]
32. Contrast-enhanced MR imaging in patients with BI-RADS 3-5 microcalcifications.
Cilotti A; Iacconi C; Marini C; Moretti M; Mazzotta D; Traino C; Naccarato AG; Piagneri V; Giaconi C; Bevilacqua G; Bartolozzi C
Radiol Med; 2007 Mar; 112(2):272-86. PubMed ID: 17361370
[TBL] [Abstract][Full Text] [Related]
33. MRI screening in a clinic population with a family history of breast cancer.
Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
[TBL] [Abstract][Full Text] [Related]
34. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Møller P; Stormorken A; Jonsrud C; Holmen MM; Hagen AI; Clark N; Vabø A; Sun P; Narod SA; Mæhle L
Breast Cancer Res Treat; 2013 May; 139(1):155-61. PubMed ID: 23615785
[TBL] [Abstract][Full Text] [Related]
35. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management.
Brennan ME; Houssami N; Lord S; Macaskill P; Irwig L; Dixon JM; Warren RM; Ciatto S
J Clin Oncol; 2009 Nov; 27(33):5640-9. PubMed ID: 19805685
[TBL] [Abstract][Full Text] [Related]
36. The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams.
Milos RI; Pipan F; Kalovidouri A; Clauser P; Kapetas P; Bernathova M; Helbich TH; Baltzer PAT
Eur Radiol; 2020 Nov; 30(11):6052-6061. PubMed ID: 32504098
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI?
Bahl M; Baker JA; Greenup RA; Ghate SV
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S435-41. PubMed ID: 26249144
[TBL] [Abstract][Full Text] [Related]
38. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.
Vreemann S; Gubern-Mérida A; Borelli C; Bult P; Karssemeijer N; Mann RM
PLoS One; 2018; 13(1):e0191399. PubMed ID: 29351560
[TBL] [Abstract][Full Text] [Related]
39. BI-RADS-MRI terminology and evaluation of intraductal carcinoma and ductal carcinoma in situ.
Tozaki M
Breast Cancer; 2013 Jan; 20(1):13-20. PubMed ID: 22109641
[TBL] [Abstract][Full Text] [Related]
40. Improving outcomes of screening breast MRI with practice evolution: initial clinical experience with 3T compared to 1.5T.
Lourenco AP; Donegan L; Khalil H; Mainiero MB
J Magn Reson Imaging; 2014 Mar; 39(3):535-9. PubMed ID: 23720144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
